{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060256","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.542432+00:00","generated_at":"2026-06-15T01:09:36.411107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health Q1 net revenue drops 25% YoY to $2.0M; OnTarget top line due Oct 2023","bullets":["Net revenue $2.0M, down 25% YoY from $2.6M and 40% QoQ from $3.3M.","Net loss to common stockholders improved to $12.2M from $18.0M YoY; EPS –$2.39 vs –$23.10.","PIPE closed raising ~$1.86M; no equity issuance before Oct 22, 2023 under agreement.","Phase 3 OnTarget trial enrollment completed; top line results expected October 2023.","IND submission for crofelemer in MVID planned Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060256","json":"https://secwatch.observer/filing/0001104659-23-060256.json","markdown":"https://secwatch.observer/filing/0001104659-23-060256.md","text":"https://secwatch.observer/filing/0001104659-23-060256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/0001104659-23-060256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/tm2315707d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:09:36.411107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95334b838f9ff8bf6a3cbf2fe592f49a619882c0","claim":"Jaguar Health, Inc. reported first quarter 2023 results: revenue $2.00 million.","evidence_excerpt":"The combined net revenue for Mytesi ® and the Company’s other prescription product, Canalevia ® -CA1, which became commercially available in April 2022, was approximately $2.00 million in the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000110465923060256/0001104659-23-060256-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"$2.00 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}